Hepatitis C News

WASHINGTON — During a session focused on the connection between the hepatitis and opioid epidemics at The Liver Meeting 2017, Jerome M. Adams, MD, MPH, Surgeon General of the U.S., advised physicians in attendance that hepatitis C elimination will require nontraditional partnerships and innovative strategies for education, prevention and screening.

WASHINGTON — Reaching sustained virologic response with direct-acting antivirals reduced the occurrence of hepatocellular carcinoma by 71%, but all treatments that cleared the virus saw a similar reduction in risk, according to a presenter at The Liver Meeting 2017.

WASHINGTON — Through treatment of hepatitis C genotype 1 with direct-acting antivirals, significant direct and indirect cost savings may arise due to fewer cases of hepatocellular carcinoma and decompensated cirrhosis, according to results of a simulated model presented at The Liver Meeting 2017. 

WASHINGTON — Most opioid users who screened positive for hepatitis C altered their substance-use behavior within 1 year, according to a presentation at The Liver Meeting 2017.

WASHINGTON — In this exclusive video from The Liver Meeting 2017, Gregory J. Dore, MBBS, PhD, FRACP, MPH, from the Kirby Institute at the University of New South Wales, Sydney, discusses the low rates of hepatitis C reinfection in people who use drugs and the safety of retreatment.

WASHINGTON — Utilizing existing primary care pharmacists allowed for an increased number of patients treated with comparable results to liver specialists, according to a presenter at The Liver Meeting 2017.

WASHINGTON — Utilizing existing primary care pharmacists allowed for an increased number of patients treated with comparable results to liver specialists, according to a presenter at The Liver Meeting 2017.

WASHINGTON — Results of a virtual trial showed that transplantation with hepatitis C-positive livers with preemptive direct-active antiviral therapy may be a viable option for improving patient survival on the liver transplant waitlist, according to an expert at The Liver Meeting 2017.

WASHINGTON — Beginning Friday, October 20, Healio Gastroenterology and Liver Disease will provide live coverage from the The Liver Meeting 2017.

Researchers found no evidence of increased rates of de novo or recurrent hepatocellular carcinoma following treatment with direct-acting antivirals compared with patients treated with interferon therapy, according to a presentation at the World Congress of Gastroenterology at ACG 2017.